New drug cocktail aims to tackle lung cancer brain metastases
NCT ID NCT07343479
First seen Jan 16, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment. The goal is to see if this approach can control the cancer for at least 6 months. Participants will receive the drugs intravenously and by mouth, and some may also get radiation to the brain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sac-TMT (a drug) combined with a third-generation EGFR-TKI (another drug), with or without radiotherapy
What this could lead to
If successful, this could offer a new treatment option for people with a specific type of lung cancer that has spread to the brain and stopped responding to standard therapy.
What could go wrong
This is an early Phase 2 trial with only 45 participants, so results may not apply to everyone. The combination may cause side effects, and it is not yet known if it works better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.